Article
Agriculture, Dairy & Animal Science
Sherri A. Powledge, Taylor B. McAtee, Amelia R. Woolums, T. Robin Falkner, John T. Groves, Merilee Thoresen, Robert Valeris-Chacin, John T. Richeson
Summary: Vaccination with modified-live virus (MLV) did not have a clear impact on the health or growth of high-risk calves, but intranasal MLV vaccination was associated with increased carriage of Histophilus somni (Hs) in the naris and reduced culture of Mannheimia haemolytica (Mh) from lung tissue samples. This suggests that intranasal MLV vaccination can alter the microbial community in the respiratory tract of cattle.
JOURNAL OF ANIMAL SCIENCE
(2022)
Review
Immunology
Aileen Ebenig, Mona Lange, Michael D. Muehlebach
Summary: Live-attenuated measles virus (MeV) has been remarkably effective in preventing measles infections, and it can also encode and express additional foreign antigens to induce effective immune responses, protecting against associated pathogens.
Review
Biochemistry & Molecular Biology
Shen Wang, Bo Liang, Weiqi Wang, Ling Li, Na Feng, Yongkun Zhao, Tiecheng Wang, Feihu Yan, Songtao Yang, Xianzhu Xia
Summary: Human diseases, especially infectious diseases and cancers, are posing unprecedented challenges to public health security and the global economy. Viral vector vaccines are prioritized as effective countermeasures against these diseases and are considered one of the best strategies for inducing robust immune responses.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Immunology
Coleen K. Cunningham, Ruth A. Karron, Petronella Muresan, Matthew S. Kelly, Elizabeth J. McFarland, Charlotte Perlowski, Jennifer Libous, Jennifer Oliva, Patrick Jean-Philippe, Jack Moye, Elizabeth Schappell, Emily Barr, Vivian Rexroad, Benjamin Johnston, Ellen G. Chadwick, Mikhaela Cielo, Mary Paul, Jaime G. Deville, Mariam Aziz, Lijuan Yang, Cindy Luongo, Peter L. Collins, Ursula J. Buchholz
Summary: Two promising live-attenuated RSV candidate vaccines were evaluated in healthy children and found to be immunogenic and capable of eliciting strong immune responses.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Marsha S. Russell, Sathya N. Thulasi Raman, Caroline Gravel, Wanyue Zhang, Annabelle Pfeifle, Wangxue Chen, Gary Van Domselaar, David Safronetz, Michael Johnston, Simon Sauve, Lisheng Wang, Michael Rosu-Myles, Jingxin Cao, Xuguang Li
Summary: A novel recombinant RSV vaccine candidate based on a deletion mutant vaccinia virus platform showed high safety and efficacy in experiments, suggesting its potential for developing new vaccines.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Chanhee Chae
Summary: PRRSV is a challenging viral pathogen in the global pork industry, with MLV vaccines being the principal strategy for control. The efficacy of the vaccines is often unpredictable and depends heavily on the field virus.
Review
Microbiology
Rogier W. Sanders, John P. Moore
Summary: Most viral vaccines work by inducing neutralizing antibodies against the virus envelope or spike glycoproteins, which are engineered for stability and presentation of key epitopes to optimize vaccine performance. This technique emerged during HIV-1 Env vaccine development and has been widely applied to other viral vaccines, including SARS-CoV-2.
CELL HOST & MICROBE
(2021)
Article
Immunology
Seong Yeon Park, Myron J. Levin, Jennifer Canniff, Michael Johnson, D. Scott Schmid, Adriana Weinberg
Summary: This study compared the antibody responses generated by Zoster Vaccine Live (ZVL) and Recombinant Zoster Vaccine (RZV). Younger vaccine recipients had higher levels of ADCC antibodies after vaccination, while older adults showed lower levels of ADCC antibodies.
Article
Microbiology
Xueqiao Liu, Hong-Su Park, Yumiko Matsuoka, Celia Santos, Lijuan Yang, Cindy Luongo, Ian N. Moore, Reed F. Johnson, Nicole L. Garza, Peng Zhang, Paolo Lusso, Sonja M. Best, Ursula J. Buchholz, Cyril Le Nouen
Summary: Intranasal immunization with the B/HPIV3/S-6P vaccine can significantly increase serum anti-S IgA/IgG levels in hamsters and induce near-sterilizing immunity. The vaccine has the potential to protect infants against both HPIV3 and SARS-CoV-2.
Review
Microbiology
Awadalkareem Adam, Christy Lee, Tian Wang
Summary: ZIKV is a re-emerging mosquito-borne flavivirus that has caused outbreaks worldwide, and it poses a major threat to global public health. The development of a safe and effective vaccine is a global health priority. Multiple platforms have been used to develop candidate ZIKV vaccines, some of which have shown promising results in animal models and progressed to clinical trials. Live-attenuated vaccines are considered one of the most important strategies for controlling flavivirus diseases.
Article
Biochemistry & Molecular Biology
Cyril Le Nouen, Christine E. Nelson, Xueqiao Liu, Hong-Su Park, Yumiko Matsuoka, Cindy Luongo, Celia Santos, Lijuan Yang, Richard Herbert, Ashley Castens, Ian N. Moore, Temeri Wilder-Kofie, Rashida Moore, April Walker, Peng Zhang, Paolo Lusso, Reed F. Johnson, Nicole L. Garza, Laura E. Via, Shirin Munir, Daniel L. Barber, Ursula J. Buchholz
Summary: This study generated a pediatric SARS-CoV-2 vaccine candidate using a live-attenuated parainfluenza virus vector, and evaluated its immunogenicity and protective efficacy in rhesus macaques. The vaccine induced strong mucosal and systemic immune responses, including neutralizing antibodies and T cell responses. Immunized macaques showed undetectable viral replication after challenge. The vaccine will be clinically evaluated as an intranasal vaccine for pediatric use.
Article
Multidisciplinary Sciences
Lorena Sanchez-Felipe, Thomas Vercruysse, Sapna Sharma, Ji Ma, Viktor Lemmens, Dominique Van Looveren, Mahadesh Prasad Arkalagud Javarappa, Robbert Boudewijns, Bert Malengier-Devlies, Laurens Liesenborghs, Suzanne J. F. Kaptein, Carolien De Keyzer, Lindsey Bervoets, Sarah Debaveye, Madina Rasulova, Laura Seldeslachts, Li-Hsin Li, Sander Jansen, Michael Bright Yakass, Babs E. Verstrepen, Kinga P. Boszormenyi, Gwendoline Kiemenyi-Kayere, Nikki van Driel, Osbourne Quaye, Xin Zhang, Sebastiaan ter Horst, Niraj Mishra, Ward Deboutte, Jelle Matthijnssens, Lotte Coelmont, Corinne Vandermeulen, Elisabeth Heylen, Valentijn Vergote, Dominique Schols, Zhongde Wang, Willy Bogers, Thijs Kuiken, Ernst Verschoor, Christopher Cawthorne, Koen Van Laere, Ghislain Opdenakker, Greetje Vande Velde, Birgit Weynand, Dirk E. Teuwen, Patrick Matthys, Johan Neyts, Hendrik Jan Thibaut, Kai Dallmeier
Summary: The candidate vaccine YF-S0, utilizing the YF17D vaccine as a vector to express noncleavable prefusion form of the SARS-CoV-2 spike antigen, showed excellent safety, immunogenicity, and efficacy in animal models. It induced high levels of neutralizing antibodies, provided protective immunity against SARS-CoV-2, and prevented infection in hamsters and macaques. A single dose was able to confer protection from lung disease in most vaccinated hamsters within 10 days, highlighting the potential of YF-S0 as a potent SARS-CoV-2 vaccine candidate.
Article
Immunology
Javier Diez-Domingo, Xavier Saez-Llorens, Miguel A. Rodriguez-Weber, Cristina Epalza, Archana Chatterjee, Cheng-Hsun Chiu, Chien-Yu Lin, Andrea A. Berry, Federico Martinon-Torres, Fernando Baquero-Artigao, Joanne M. Langley, Jose T. Ramos Amador, Joseph B. Domachowske, Li-Min Huang, Nan-Chang Chiu, Susanna Esposito, Philippe Moris, Thi Lien-Anh Nguyen, Vanja Nikic, Wayne Woo, Yingjun Zhou, Ilse Dieussaert, Amanda Leach, Antonio Gonzalez Lopez, Nicolas Vanhoutte
Summary: This study tested a new candidate RSV vaccine in toddlers who had a previous RSV infection. The vaccine was effective in preventing RSV-related illnesses and triggered an antibody response that could neutralize the virus. No vaccine-related serious adverse events or RSV-related hospitalizations were reported during the study.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Review
Virology
Brent A. Stanfield, Konstantin G. Kousoulas, Agustin Fernandez, Edward Gershburg
Summary: Diseases caused by human herpes simplex virus types 1 and 2 affect millions worldwide, but there are currently no FDA-approved vaccines. The development of novel live-attenuated vaccines aims to prevent or reduce the impact of herpes simplex infections, building on the success of past live-attenuated vaccines in combating viral diseases. These vaccines are designed to generate robust and protective immune responses based on our understanding of the immunopathogenesis of herpesviral infections.
Review
Immunology
Camila Covian, Mariana Rios, Roslye Berrios-Rojas, Susan M. Bueno, Alexis M. Kalergis
Summary: Vaccines play a crucial role in protecting humans from various pathogens and can induce trained immunity, providing non-specific memory against a wide range of pathogens. Recombinant BCG vaccines have shown potential in combating respiratory syncytial virus and metapneumovirus by simultaneously inducing specific adaptive immunity and non-specific trained immunity, offering broader protection against pathogenic viruses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Iebe Rossey, Morgan S. A. Gilman, Stephanie C. Kabeche, Koen Sedeyn, Daniel Wrapp, Masaru Kanekiyo, Man Chen, Vicente Mas, Jan Spitaels, Jose A. Melero, Barney S. Graham, Bert Schepens, Jason S. McLellan, Xavier Saelens
NATURE COMMUNICATIONS
(2017)
Review
Biochemistry & Molecular Biology
Iebe Rossey, Jason S. McLellan, Xavier Saelens, Bert Schepens
TRENDS IN MICROBIOLOGY
(2018)
Article
Immunology
Iebe Rossey, Koen Sedeyn, Sarah De Baets, Bert Schepens, Xavier Saelens
Article
Virology
Iebe Rossey, Ching-Lin Hsieh, Koen Sedeyn, Marlies Ballegeer, Bert Schepens, Jason S. Mclellan, Xavier Saelens
Summary: This study identified a prefusion F-specific VHH that primarily binds to antigenic site I of RSV F. The VHH neutralizes RSV A at subnanomolar concentrations, highlighting a previously underappreciated membrane-proximal region sensitive to neutralization. These findings contribute to insights into the RSV F antigenic map.
JOURNAL OF VIROLOGY
(2021)
Article
Cell Biology
Bert Schepens, Loes van Schie, Wim Nerinckx, Kenny Roose, Wander Van Breedam, Daria Fijalkowska, Simon Devos, Wannes Weyts, Sieglinde De Cae, Sandrine Vanmarcke, Chiara Lonigro, Hannah Eeckhaut, Dries Van Herpe, Jimmy Borloo, Ana Filipa Oliveira, Joao Paulo Portela Catani, Sarah Creytens, Dorien De Vlieger, Gitte Michielsen, Jackeline Cecilia Zavala Marchan, George D. Moschonas, Iebe Rossey, Koen Sedeyn, Annelies Van Hecke, Xin Zhang, Lana Langendries, Sofie Jacobs, Sebastiaan Ter Horst, Laura Seldeslachts, Laurens Liesenborghs, Robbert Boudewijns, Hendrik Jan Thibaut, Kai Dallmeier, Greetje Vande Velde, Birgit Weynand, Julius Beer, Daniel Schnepf, Annette Ohnemus, Isabel Remory, Caroline S. Foo, Rana Abdelnabi, Piet Maes, Suzanne J. F. Kaptein, Joana Rocha-Pereira, Dirk Jochmans, Leen Delang, Frank Peelman, Peter Staeheli, Martin Schwemmle, Nick Devoogdt, Dominique Tersago, Massimiliano Germani, James Heads, Alistair Henry, Andrew Popplewell, Mark Ellis, Kevin Brady, Alison Turner, Bruno Dombrecht, Catelijne Stortelers, Johan Neyts, Nico Callewaert, Xavier Saelens
Summary: Camelid-derived single domain antibodies (VHHs) have potential for neutralizing both SARS-CoV-1 and SARS-CoV-2 variants. Researchers have successfully developed a VHH-Fc fusion protein that can neutralize SARS-CoV-2 and demonstrated good antiviral effects in mouse and hamster models.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Review
Virology
Tessa Van Royen, Iebe Rossey, Koen Sedeyn, Bert Schepens, Xavier Saelens
Summary: RSV infection inhibits host's innate immune response through multiple proteins, including suppression of interferon production and signaling, reduction of immune cell recruitment and cytokine production, and negative effects on mitochondrial proteins.
Review
Immunology
Dorien De Vlieger, Marlies Ballegeer, Iebe Rossey, Bert Schepens, Xavier Saelens
